Evidence map›Paper›PMID 42583969›Full record

Trial reportIndian journal of pharmacology2026

Efficacy and safety of different doses of apremilast in mild to-moderate psoriasis: A randomized controlled study.

Abhishek Anil, Aswini Saravanan, Anil Budania, Isha Yadav, Pradeep Dwivedi, Shoban Babu Varthya, Sneha Ambwani, Surjit Singh

Abstract readRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Indian journal of pharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Abhishek AnilDepartment of Pharmacology, Venereology and Leprology, All India Institute of Medical Sciences, Jodhpur, Rajasthan, India.
Aswini SaravananDepartment of Pharmacology, Venereology and Leprology, All India Institute of Medical Sciences, Jodhpur, Rajasthan, India.
Anil BudaniaDepartment of Dermatology, Venereology and Leprology, All India Institute of Medical Sciences, Jodhpur, Rajasthan, India.
Isha YadavDepartment of Pharmacology, Venereology and Leprology, All India Institute of Medical Sciences, Jodhpur, Rajasthan, India.
Pradeep DwivediDepartment of Pharmacology, Venereology and Leprology, All India Institute of Medical Sciences, Jodhpur, Rajasthan, India.
Shoban Babu VarthyaDepartment of Pharmacology, Venereology and Leprology, All India Institute of Medical Sciences, Jodhpur, Rajasthan, India.
Sneha AmbwaniDepartment of Pharmacology, Venereology and Leprology, All India Institute of Medical Sciences, Jodhpur, Rajasthan, India.
Surjit SinghDepartment of Pharmacology, Venereology and Leprology, All India Institute of Medical Sciences, Jodhpur, Rajasthan, India.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectivesApremilast, proven to be effective against psoriasis, has many side effects at the standard dose of 30 mg, impacting adherence. Hence, we aimed to compare the lower doses (10 mg and 20 mg) to the 30 mg apremilast dose. Primary objectives were to compare psoriasis area and severity index (PASI) 75 response and adverse events (AEs) in apremilast 30 mg versus 20 mg, and 30 mg versus 10 mg from baseline to 16th week.

methodsIn this randomized, active-controlled trial, 124 patients with mild to moderate psoriasis were randomized (1:1:1 ratio) to apremilast 10 mg, 20 mg, or 30 mg twice daily for 16 weeks. Efficacy parameters were evaluated at 16th week, and safety was monitored every 2 weeks.

resultsAt week 16, PASI 75 response was comparable between apremilast 30 mg (31.7%) and 20 mg (28.6%) (P = 0.756), but significantly higher than 10 mg (9.8%) (P = 0.014). Apremilast 30 mg and 20 mg demonstrated comparable static physician global assessment 0/1 responses (39% vs. 31%, P = 0.441), whereas 30 mg significantly outperformed 10 mg (12.2%, P = 0.005). Common AEs observed in all groups were nausea and headache. Apremilast 30 mg exhibited significantly more AEs than 20 mg (P = 0.023) and 10 mg (P = 0.001).

conclusionApremilast 20 mg demonstrated comparable efficacy with significantly fewer side effects than the 30 mg dose in mild-to-moderate psoriasis, while apremilast 10 mg showed no significant improvement in efficacy compared to the 30 mg dose.

Indexed as

Anti-Inflammatory Agents, Non-SteroidalPsoriasisThalidomideAdultDose-Response Relationship, DrugFemaleHumansMaleMiddle AgedSeverity of Illness IndexTreatment OutcomeAnti-Inflammatory Agents, Non-SteroidalapremilastThalidomideApremilastdermatologypsoriasisrandomized trial

Identifiers

PMID42583969
PMCPMC13412499

What Socratic holds

Textmetadata
LicenceCC BY-NC-SA
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.